Dren Bio expands strategic collaboration with Sanofi

Dren Bio, a privately held, US clinical-stage biotechnology company developing first-in-class myeloid cell engager therapeutics, announced today that it has entered into a strategic collaboration with Sanofi (Euronext: SAN) for the discovery and development of a next-generation B-cell depleting therapy for the treatment of various autoimmune diseases.

The new agreement builds on the existing relationship between the two companies, following Sanofi’s acquisition earlier this year of Dren Bio’s DR-0201 program for deep B-cell depletion. DR-0201, now known as SAR448501, is currently being evaluated in two ongoing Phase I studies and has shown robust B-cell depletion, with the potential to induce sustained treatment-free remission in patients with autoimmune diseases. The DR-0201 deal had the potential for Dren Bio to earn $1.3 billion.

Deal worth up to $1.7 billion